NASDAQ:ASRT Assertio (ASRT) Stock Price, News & Analysis $1.50 +0.03 (+2.03%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.48▼$1.5850-Day Range$0.93▼$1.7552-Week Range$0.73▼$5.78Volume1.57 million shsAverage Volume1.08 million shsMarket Capitalization$143.16 millionP/E RatioN/ADividend YieldN/APrice Target$4.15 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Assertio alerts: Email Address Assertio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside175.7% Upside$4.15 Price TargetShort InterestHealthy7.02% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 7 Articles This WeekInsider TradingAcquiring Shares$35,350 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.13) to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.95 out of 5 starsMedical Sector423rd out of 936 stocksPharmaceutical Preparations Industry193rd out of 436 stocks 3.5 Analyst's Opinion Consensus RatingAssertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAssertio has only been the subject of 3 research reports in the past 90 days.Read more about Assertio's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.02% of the outstanding shares of Assertio have been sold short.Short Interest Ratio / Days to CoverAssertio has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Assertio has recently decreased by 28.25%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAssertio does not currently pay a dividend.Dividend GrowthAssertio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASRT. Previous Next 3.2 News and Social Media Coverage News SentimentAssertio has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Assertio this week, compared to 3 articles on an average week.Search Interest29 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 123% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Assertio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $35,350.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Assertio is held by insiders.Percentage Held by Institutions48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Assertio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Assertio are expected to grow in the coming year, from ($0.13) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Assertio is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Assertio is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAssertio has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Assertio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. About Assertio Stock (NASDAQ:ASRT)Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.Read More ASRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASRT Stock News HeadlinesJuly 24 at 4:05 PM | globenewswire.comAssertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024July 24 at 10:59 AM | finance.yahoo.comBuxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc.July 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.July 9, 2024 | globenewswire.comAssertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 3, 2024 | globenewswire.comASSERTIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Assertio Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmJune 24, 2024 | 247wallst.com3 Penny Stocks With 458% Average Upside According to Wall Street AnalystsJune 6, 2024 | globenewswire.comAssertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5, 2024 | globenewswire.comAssertio to Participate in the Sidoti Small Cap Conference on June 12, 2024July 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.May 29, 2024 | markets.businessinsider.comAssertio Names O'Grady CEOMay 29, 2024 | finance.yahoo.comAssertio Announces the Appointment of Brendan P. O’Grady as New CEOMay 29, 2024 | msn.comAlliance Global Partners Initiates Coverage of Assertio Holdings (ASRT) with Buy RecommendationMay 17, 2024 | globenewswire.comAssertio to Participate in Benchmark Healthcare Conference on May 21-22May 17, 2024 | prnewswire.comBUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORSMay 16, 2024 | globenewswire.comAssertio to Participate in AGP Healthcare Conference on May 21May 13, 2024 | prnewswire.comBUXTON HELMSLEY URGES ASSERTIO STOCKHOLDERS TO VOTE "AGAINST" DIRECTORS AFTER DISCLOSURE FAILURES, INAPPROPRIATE BOARDROOM ACTIVITY, STRATEGIC BLUNDERSMay 10, 2024 | globenewswire.comAssertio to Present at the Citizens JMP Life Sciences Conference in New York CityMay 8, 2024 | finance.yahoo.comAssertio Holdings First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsSee More Headlines Receive ASRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Assertio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Confirmed)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASRT CUSIPN/A CIK1808665 Webwww.assertiotx.com Phone(224) 419-7106Fax510-744-8001Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$4.15 High Stock Price Target$7.00 Low Stock Price Target$2.75 Potential Upside/Downside+194.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($3.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-331,940,000.00 Net Margins-234.40% Pretax Margin-177.99% Return on Equity10.80% Return on Assets5.74% Debt Debt-to-Equity Ratio0.29 Current Ratio1.87 Quick Ratio1.45 Sales & Book Value Annual Sales$152.07 million Price / Sales0.94 Cash Flow$0.72 per share Price / Cash Flow2.09 Book Value$1.46 per share Price / Book1.03Miscellaneous Outstanding Shares95,120,000Free Float92,081,000Market Cap$143.16 million OptionableOptionable Beta0.90 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMs. Heather L. Mason (Age 64)Interim CEO & Director Comp: $92.5kMr. Ajay Patel (Age 40)Senior VP & CFO Comp: $538.79kMr. Paul Schwichtenberg (Age 53)Senior Vice President & Chief Commercial Officer Comp: $573.65kMr. Bill IskosSenior Vice President of OperationsMs. Molly DirSenior Vice President of HR & Administration ?Mr. Sam Schlessinger (Age 42)Senior VP & General Counsel Dr. Howard J. Franklin M.B.A.M.D., Senior Vice President of MedicalMore ExecutivesKey CompetitorsSavaraNASDAQ:SVRAApplied TherapeuticsNASDAQ:APLTPharming GroupNASDAQ:PHARLarimar TherapeuticsNASDAQ:LRMRAvid BioservicesNASDAQ:CDMOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpSold 230,404 shares on 7/26/2024Ownership: 0.370%SummerHaven Investment Management LLCBought 15,779 shares on 7/24/2024Ownership: 0.169%Jeff L VacircaBought 10,000 shares on 6/11/2024Total: $11,100.00 ($1.11/share)Heather L MasonBought 25,000 shares on 6/5/2024Total: $24,250.00 ($0.97/share)Vanguard Group Inc.Bought 41,071 shares on 5/10/2024Ownership: 5.172%View All Insider TransactionsView All Institutional Transactions ASRT Stock Analysis - Frequently Asked Questions How have ASRT shares performed this year? Assertio's stock was trading at $1.07 at the beginning of 2024. Since then, ASRT shares have increased by 40.7% and is now trading at $1.5050. View the best growth stocks for 2024 here. How were Assertio's earnings last quarter? Assertio Holdings, Inc. (NASDAQ:ASRT) issued its earnings results on Monday, May, 6th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.04. The firm had revenue of $32.45 million for the quarter, compared to analyst estimates of $28.93 million. Assertio had a negative net margin of 234.40% and a positive trailing twelve-month return on equity of 10.80%. Who are Assertio's major shareholders? Top institutional investors of Assertio include Bank of New York Mellon Corp (0.37%), SummerHaven Investment Management LLC (0.17%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include Daniel A Peisert, William Mckee, Heather L Mason, Jeff L Vacirca, Ajay Patel, Sam Schlessinger and Paul Schwichtenberg. View institutional ownership trends. How do I buy shares of Assertio? Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Assertio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), VBI Vaccines (VBIV), InterDigital (IDCC), Trevena (TRVN) and This page (NASDAQ:ASRT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assertio Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assertio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.